natgillin/translations-raw huggingface dataset:
Co-administration may result in competitive inhibition of the metabolism of these medicinal products and create the potential for serious and/ or life-threatening adverse events such as cardiac arrhythmia (e. g. amiodarone, bepridil, quinidine, terfenadine, astemizole, cisapride, pimozide), respiratory depression and / or prolonged sedation (e. g. oral triazolam and oral midazolam (for caution on parenterally administered midazolam, see section 4.5)) or peripheral vasospasm or ischaemia and ischaemia of other tissues, including cerebral or myocardial ischaemia (e. g. ergot derivatives).
Sočasna uporaba ima lahko za posledico kompetitivno inhibicijo presnavljanja teh zdravil in izzove možnost hujših in/ ali življenjsko usodnih neželenih učinkov, kot so: aritmija (npr. amiodaron, bepridil, kinidin, terfenadin, astemizol, cisaprid, pimozid), depresija dihanja in/ ali podaljšana sedacija (npr. peroralna uporaba triazolama ali midazolama (glede previdnostnih ukrepov ob parenteralni uporabi midazolama glejte poglavje 4. 5)) ali periferni vazospazem ali ishemija in ishemija drugih tkiv, vključno s cerebralno ali miokardno ishemijo (npr. derivati ergot alkaloidov).
(see section 4.5).
Kombinacija rifampicina in zdravila Agenerase skupaj z nizkim odmerkom ritonavirja je kontraindicirana (glejte poglavje 4. 5).
Agenerase with ritonavir must not be co-administered with medicinal products with narrow therapeutic windows that are highly dependent on CYP2D6 metabolism, e. g. flecainide and propafenone (see section 4.5).
Zdravilo Agenerase v kombinaciji z ritonavirjem se ne sme dajati sočasno z zdravili ozke terapevtske širine, ki so močno odvisni od presnove z CYP2D6, npr. flekainid in propafenon (glejte poglavje 4. 5).
Herbal preparations containing St John’ s wort (Hypericum perforatum) must not be used while taking amprenavir due to the risk of decreased plasma concentrations and reduced clinical effects of amprenavir (see section 4.5).
Zeliščni pripravki s šentjanževko (Hypericum perforatum) se zaradi nevarnosti znižanja plazemskih koncentracij in manjše klinične učinkovitosti amprenavirja ne smejo uporabljati sočasno z amprenavirjem (glejte poglavje 4. 5).
3 4.4 Special warnings and precautions for use
3 4. 4 Posebna opozorila in previdnostni ukrepi
When amprenavir is administered as monotherapy, resistant viruses rapidly emerge (see section 5.1).
V primeru monoterapije z amprenavirjem se hitro pojavijo rezistentni virusi (glejte poglavje 5. 1).
Agenerase capsules should normally be given in combination with low dose ritonavir and in combination with other antiretroviral agents (see section 4.2).
Kapsule Agenerase se morajo praviloma dajati v kombinaciji z nizkim odmerkom ritonavirja in v kombinaciji z drugimi protiretrovirusnimi zdravili (glejte poglavje 4. 2).
Liver Disease:
Jetrno obolenje:
The safety and efficacy of amprenavir has not been established in patients with significant underlying liver disorders.
Pri bolnikih z znatnimi osnovnimi boleznimi jeter varnost in učinkovitost amprenavirja nista bili dokazani.
Agenerase capsules are contraindicated in patients with severe hepatic impairment when used in combination with ritonavir (see section 4.3).
Uporaba kapsul Agenerase v kombinaciji z ritonavirjem je kontraindicirana pri bolnikih s hudo obliko oslabljenega delovanja jeter (glejte poglavje 4. 3).
Concomitant use of Agenerase with ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing’ s syndrome and adrenal suppression (see section 4.5).
Sočasne uporabe zdravila Agenerase v kombinaciji z ritonavirjem in flutikazonom ali drugimi glukokortikoidi, ki se presnavljajo s CYP3A4, ne priporočamo, razen v primerih, ko možne koristi zdravljenja prevladajo nad tveganjem za pojav sistemskih kortikosteroidnih učinkov, vključno s Cushingovim sindromom in z zaviralnim vplivom na nadledvično žlezo (glejte poglavje 4. 5).
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin are recommended (see section 4.5).
Ob indikacijah za zdravljenje z zaviralci HMG- CoA reduktaze sta priporočena pravastatin ali fluvastatin (glejte poglavje 4. 5).
For some medicinal products that can cause serious or life-threatening undesirable effects, such as carbamazepine, phenobarbital, phenytoin, tricyclic antidepressants and warfarin (monitor International Normalised Ratio), concentration monitoring is available; this should minimise the risk of potential safety problems with concomitant use.
Za ta zdravila so na razpolago metode za nadziranje njihovih koncentracij; slednje naj bi zmanjšalo tveganje za pojav možnih težav glede varnosti ob sočasni uporabi.
The use of Agenerase concomitantly with halofantrine or lidocaine (systemic) is not recommended (see section 4.5).
Sočasne uporabe zdravila Agenerase in halofantrina ali lidokaina (sistemskega) ne priporočamo (glejte poglavje 4. 5).
Agenerase may be less effective due to decreased amprenavir plasma concentrations in patients taking these medicinal products concomitantly (see section 4.5).
Pri bolnikih, ki jemljejo omenjena zdravila sočasno z zdravilom Agenerase se učinkovitost slednjega lahko zmanjša zaradi zmanjšanih koncentracij amprenavirja v plazmi (glejte poglavje 4. 5).
Therapeutic concentration monitoring is recommended for immunosuppressant medicinal products (cyclosporine, tacrolimus, rapamycin) when co-administered with Agenerase (see section 4.5).
4 Priporočamo nadziranje terapevtskih koncentracij zdravil za zaviranje imunske odzivnosti (ciklosporin, takrolimus, rapamicin), če se jih uporablja skupaj z zdravilom Agenerase (glejte poglavje 4. 5).
Caution is advised when Agenerase is used concomitantly with PDE5 inhibitors (e. g. sildenafil and vardenafil) (see section 4.5).
Pri sočasni uporabi zdravila Agenerase in zaviralcev PDE5 (npr. sildenafil in vardenafil) svetujemo previdnost (glejte poglavje 4. 5).
4 Caution is advised when Agenerase is used concomitantly with delavirdine (see section 4.5).
Pri sočasni uporabi zdravila Agenerase in delavirdina svetujemo previdnost (glejte poglavje 4. 5).
A reduction of rifabutin dosage of at least 50% is recommended when administered with Agenerase.
Če se rifabutin daje sočasno z zdravilom Agenerase priporočamo, da se odmerek rifabutina zmanjša vsaj za 50%.
When ritonavir is co-administered further dose reduction may be necessary (see section 4.5).
Pri sočasnem dajanju ritonavirja bo morda odmerek rifabutina potrebno še nadalje zmanjšati (glejte poglavje 4. 5).
Therefore, alternative reliable methods of contraception are recommended for women of childbearing potential (see section 4.5).
Pri ženskah v rodni dobi se tako priporočajo druge, učinkovite in varne kontracepcijske metode (glejte poglavje 4. 5).
No recommendations can currently be made regarding adjustment of amprenavir dose when amprenavir is co-administered with methadone.
Priporočil glede prilagajanja odmerka amprenavirja, če se le- ta uporablja sočasno z metadonom, trenutno ne moremo podati.
Agenerase capsules contain vitamin E (36 IU/ 50 mg capsule), therefore additional vitamin E supplementation is not recommended.
Kapsule Agenerase vsebujejo vitamin E (36 i. e. / 50 mg kapsulo), zato ni priporočljiva dodatna uporaba vitamina E.
Rash / cutaneous reactions
Eksantem/ kožne reakcije
Appropriate antihistamines (e. g. cetirizine dihydrochloride) may reduce pruritus and hasten the resolution of rash.
Ustrezen antihistaminik (npr. cetirizinijev diklorid) lahko omili srbež in pospeši resolucijo izpuščaja.
Agenerase should be permanently discontinued when rash is accompanied with systemic symptoms or allergic symptoms or mucosal involvement (see section 4.8).
Če eksantem spremljajo sistemski znaki, znaki alergije ali prizadetost sluznic, je potrebno uporabo zdravila Agenerase trajno ukiniti (glejte poglavje 4. 8).
Knowledge about the mechanism is incomplete.
Pri bolnikih, okuženih z virusom HIV, je bilo kombinirano protiretrovirusno zdravljenje povezano s prerazdelitvijo telesnega maščevja (lipodistrofija).
A connection between visceral lipomatosis and protease inhibitors and lipoatrophy and nucleoside reverse transcriptase inhibitors has been hypothesised.
Dolgotrajne posledice takšnega dogajanja trenutno niso poznane, vedenje o mehanizmu pa je nepopolno.
Lipid disorders should be managed as clinically appropriate (see section 4.8).
Domneva se, da gre za povezavo med visceralno lipomatozo in zaviralci proteaz ter lipoatrofijo in nukleozidnimi in nukleotidnimi zaviralci reverzne
5 Haemophiliac patients
5 transkriptaze.
Relevant examples are cytomegalovirus retinitis, generalised and/ or focal mycobacterium infections, and Pneumocystis carinii pneumonia.
Ustrezni primeri so citomegalovirusni retinitis, generalizirane in/ ali žariščne okužbe z mikobakterijami in s Pneumocystis carinii povzročena pljučnica.
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/ or long-term exposure to combination antiretroviral therapy (CART).
Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART – combination antiretroviral therapy) ali obojim.
Associations contraindicated (see section 4.3)
Povezave s kontraindikacijami (glejte poglavje 4. 3)
Co-administration may result in competitive inhibition of the metabolism of these active substances thus increasing their plasma level and leading to serious and / or life-threatening adverse reactions such as cardiac arrhythmia (e. g. amiodarone, astemizole, bepridil, cisapride, pimozide, quinidine, terfenadine) or peripheral vasospasm or ischaemia (e. g. ergotamine, dihydroergotamine).
Zaradi sočasne uporabe se lahko pojavi kompetitivna presnova teh učinkovin in posledično povečanje njihovih plazemskih vrednosti, kar lahko povzroči resne in/ ali smrtno nevarne neželene reakcije, kot so aritmije (npr. amiodaron, astemizol, bepridil, cisaprid, pimozid, kinidin, terfenadin) ali periferni vazospazem ali ishemija (npr. ergotamin, dihidroergotamin).
CYP2D6 substrates with narrow therapeutic index Agenerase with ritonavir must not be co-administered with medicinal products containing active substances that are highly dependent on CYP2D6 metabolism and for which elevated plasma concentrations are associated with serious and / or life-threatening adverse reactions.
6 Substrati za CYP2D6 z ozkim terapevtskim indeksom Zdravilo Agenerase v kombinaciji z ritonavirjem se ne sme dajati sočasno z zdravili, katerih učinkovine so močno odvisne od presnove s CYP2D6 in katerih povečane koncentracije v plazmi so povezane z resnimi in/ ali smrtno nevarnimi neželenimi reakcijami.
Rifampicin
Rifampicin Rifampicin je močan induktor CYP3A4.
6 Rifampicin is a strong CYP3A4 inducer and has been shown to cause an 82% decrease in amprenavir AUC, which can result in virological failure and resistance development.
Posledica tega je lahko upad protivirusnega delovanja in razvoj rezistence.
The combination of rifampicin and Agenerase with concomitant low-dose ritonavir is contraindicated (see section 4.3).
Kombinacija rifampicina in zdravila Agenerase skupaj z nizkim odmerkom ritonavirja je kontraindicirana (glejte poglavje 4. 3).
St John’ s wort (Hypericum perforatum) Serum levels of amprenavir can be reduced by concomitant use of the herbal preparation St John’ s wort (Hypericum perforatum).
Šentjanževka (Hypericum perforatum) Serumske koncentracije amprenavirja se lahko ob sočasni uporabi rastlinskih pripravkov iz šentjanževke (Hypericum perforatum) znižajo.
This is due to induction of drug metabolising enzymes by St John’ s wort.
Slednje je posledica šentjanževkine indukcije presnovnih encimov zdravila.
Herbal preparations containing St John’ s wort should therefore not be combined with Agenerase.
Rastlinski pripravki iz šentjanževke se torej ne smejo kombinirati z zdravilom Agenerase.
If a patient is already taking St John’ s wort, check amprenavir and if possible viral levels and stop St John’ s wort.
Če bolnik že jemlje pripravke iz šentjanževke, je potrebno preveriti vrednosti amprenavirja in po možnosti virusa ter prenehati jemati pripravke iz šentjanževke.
Amprenavir levels may increase on stopping St John’ s wort.
Ob prenehanju jemanja pripravkov iz šentjanževke se lahko vrednosti amprenavirja zvišajo.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’ s wort.
Inducirajoči učinek lahko vztraja še najmanj 2 tedna po opustitvi zdravljenja s pripravki iz šentjanževke.
• Protease inhibitors (PIs):
• Zaviralci proteaz (PI- ji):
Indinavir: the AUC, Cmin and Cmax of indinavir were decreased by 38%, 27%, and 22%, respectively, when given with amprenavir.
Ob sočasnem dajanju z amprenavirjem so se AUC, Cmin in Cmax indinavirja zmanjšale, in sicer AUC za 38%, Cmin za 27% in Cmax za 22%.
The AUC, Cmin and Cmax of amprenavir were increased by 33%, 25%, and 18%, respectively.
AUC za 33%, Cmin za 25% in Cmax za 18%.
Saquinavir: the AUC, Cmin and Cmax of saquinavir were decreased by 19% and 48% and increased by 21%, respectively, when given with amprenavir.
Ob sočasnem dajanju z amprenavirjem sta se AUC in Cmin sakvinavirja zmanjšali, in sicer AUC za 19%, Cmin pa za 48%; Cmax sakvinavirja se je zvišala za 21%.
The AUC, Cmin and Cmax of amprenavir were decreased by 32%, 14%, and 37%, respectively.
AUC za 32%, Cmin za 14% in Cmax za 37%.
Nelfinavir: the AUC, Cmin and Cmax of nelfinavir were increased by 15%, 14%, and 12%, respectively, when given with amprenavir.
Ob sočasnem dajanju z amprenavirjem so se AUC, Cmin in Cmax nelfinavirja zvečale, in sicer AUC za 15%, Cmin za 14% in Cmax za 12%.
The Cmax of amprenavir was decreased by 14% whilst the AUC and Cmin were increased by 9% and 189%, respectively.
Cmax amprenavirja se je znižala za 14%, medtem ko sta se AUC in Cmin amprenavirja zvečali, in sicer AUC za 9% ter Cmin za 189%.
Ritonavir: the AUC and Cmin of amprenavir were increased by 64% and 508% respectively and the Cmax decreased by 30% when ritonavir (100 mg twice daily) was co-administered with amprenavir capsule (600 mg twice daily) compared to values achieved after 1200 mg twice daily doses of amprenavir capsules.
Cmax amprenavirja se je znižala za 30%.
Lopinavir / ritonavir (Kaletra): in an open-label, non-fasting pharmacokinetic study, the AUC, Cmax and Cmin of lopinavir were decreased by 38%, 28% and 52% respectively when amprenavir (750 mg twice daily) was given in combination with Kaletra (400 mg lopinavir + 100 mg ritonavir twice daily).
V odprti farmakokinetični študiji so se AUC, Cmax in Cmin lopinavirja zmanjšale, in sicer AUC za 38%, Cmax za 28% in Cmin za 52%, če so amprenavir (750 mg dvakrat dnevno) dajali v kombinaciji z zdravilom Kaletra (400 mg lopinavirja + 100 mg ritonavirja dvakrat dnevno).
In the same study, the AUC, Cmax, and Cmin of amprenavir were increased 72%, 12%, and 483%, respectively, when compared to values after standard doses of amprenavir (1200 mg twice daily).
7 amprenavirja (1200 mg dvakrat dnevno), AUC, Cmax in Cmin amprenavirja zvečale, in sicer AUC za 72%, Cmax za 12% in Cmin za 483%.
The amprenavir plasma Cmin values achieved with the combination of amprenavir (600 mg twice daily) in combination with Kaletra (400 mg lopinavir + 100 mg ritonavir twice daily) are approximately 40- 50% lower than when amprenavir (600 mg twice daily) is given in combination with ritonavir 100 mg twice daily.
Dosežene vrednosti Cmin amprenavirja v plazmi po dajanju amprenavirja (600 mg dvakrat dnevno) v kombinaciji z zdravilom Kaletra (400 mg lopinavirja + 100 mg ritonavirja dvakrat dnevno) so bile približno za 40– 50% nižje kot po dajanju kombinacije amprenavir (600 mg dvakrat dnevno) plus ritonavir (100 mg dvakrat dnevno).
No dose recommendation can be given for the co-
Dodatno dodajanje ritonavirja h kombinaciji amprenavir plus zdravilo Kaletra je zvišalo vrednosti Cmin lopinavirja, ne pa vrednosti Cmin amprenavirja.
7 administration of amprenavir and Kaletra, but close monitoring is advised because the safety and efficacy of this combination is unknown.
Glede sočasnega dajanja amprenavirja in zdravila Kaletra ne moremo podati priporočenih odmerkov, svetujemo pa temeljito nadziranje, saj sta varnost in učinkovitost takšne kombinacije neznani.
• Nucleoside analogue reverse transcriptase inhibitors (NRTIs):
• Zaviralci nukleotidne in nukleozidne reverzne transkriptaze (NRTI- ji):
Zidovudine: the AUC and Cmax of zidovudine were increased by 31% and 40%, respectively, when given with amprenavir.
Ob sočasnem dajanju z amprenavirjem sta se AUC in Cmax zidovudina zvečali, in sicer AUC za 31% ter Cmax za 40%.
Lamivudine: the AUC and Cmax of lamivudine and amprenavir, respectively, were both unaltered when these two medicinal products were given concomitantly.
Ob sočasnem dajanju z amprenavirjem sta AUC in Cmax lamivudina in amprenavirja ostali nespremenjeni.
Abacavir: the AUC, Cmin and Cmax of abacavir were unaltered when given with amprenavir.
AUC, Cmin in Cmax amprenavirja so se zvečale:
The AUC, Cmin and Cmax of amprenavir were increased by 29%, 27%, and 47%, respectively.
AUC za 29%, Cmin za 27% in Cmax za 47%.
Didanosine: no pharmacokinetic study has been performed with Agenerase in combination with didanosine, however, due to its antacid component, it is recommended that didanosine and Agenerase should be administered at least one hour apart (see Antacids below).
Farmakokinetične študije o sočasni uporabi zdravila Agenerase in didanozina niso bile izvedene, vendar se zaradi njegovega antacidnega delovanja priporoča, da se didanozin in zdravilo Agenerase uporabljata vsaj z enournim presledkom (glejte Antacidi spodaj).
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
• Nenukleozidni zaviralci reverzne transkriptaze (NNRTI- ji):
Efavirenz: efavirenz has been seen to decrease the Cmax, AUC and Cmin, ss of amprenavir by approximately 40% in adults.
Pri odraslih je bilo opaženo, da efavirenz zmanjša Cmax, AUC in Cmin, ss amprenavirja za približno 40%.
The effect of nevirapine on other protease inhibitors and the limited evidence available suggest that nevirapine may decrease the serum concentrations of amprenavir.
Učinek nevirapina na druge zaviralce proteaz in omejenost razpoložljivih dokazov dopuščata možnost, da lahko nevirapin zniža serumsko koncentracijo amprenavirja.
Delavirdine: the AUC, Cmax and Cmin of delavirdine were decreased by 61%, 47% and 88% respectively when given with amprenavir.
Ob sočasnem dajanju z amprenavirjem so se AUC, Cmax in Cmin delavirdina zmanjšale, in sicer AUC za 61%, Cmax za 47% in Cmin za 88%.
The AUC, Cmax and Cmin of amprenavir were increased by 130%, 40% and 125% respectively.
AUC za 130%, Cmax za 40% in Cmin za 125%.
If these medicinal products are used concomitantly care is advised, and close clinical and virological monitoring should be performed since it is difficult to predict the effect of the combination of amprenavir and ritonavir on delavirdine.
Ob hkratni uporabi teh dveh zdravil svetujemo previdnost, saj je zaradi znižanih in potencialno subterapevtskih koncentracij delavirdina v plazmi njegova učinkovitost lahko zmanjšana.
8 Antibiotics/ antifungals
8 Za sočasno uporabo amprenavirja, nizkih odmerkov ritonavirja in delavirdina ne moremo podati priporočenih odmerkov.
Rifabutin: co-administration of amprenavir with rifabutin resulted in a 193% increase in rifabutin AUC and an increase of rifabutin-related adverse events.
Sočasna uporaba amprenavirja z rifabutinom je imela za posledico zvečanje AUC rifabutina za 193%, hkrati pa je tudi narasla pogostnost z rifabutinom povezanih neželenih učinkov.
Clarithromycin: the AUC and Cmin of clarithromycin were unaltered and the Cmax decreased by 10% when given with amprenavir.
Ob sočasni uporabi z amprenavirjem sta AUC in Cmin klaritromicina ostali nespremenjeni, Cmax klaritromicina pa se je znižala za 10%.
The AUC, Cmin and Cmax of amprenavir were increased by 18%, 39% and 15%, respectively.
AUC, Cmin in Cmax amprenavirja so se zvečale, in sicer AUC za 18%, Cmin za 39% in Cmax za 15%.
Erythromycin: no pharmacokinetic study has been performed with Agenerase in combination with erythromycin, however, plasma levels of both medicinal products may be increased when co-administered.
Farmakokinetične študije o uporabi zdravila Agenerase v kombinaciji z eritromicinom niso bile izvedene, vendar lahko pride ob sočasni uporabi do porasta plazemskih koncentracij obeh zdravil.
Ketoconazole / Itraconazole: the AUC and Cmax of ketoconazole were increased by 44% and 19%, respectively when given with amprenavir alone.
Pri sočasni uporabi ketokonazola in amprenavirja sta se AUC in Cmax ketokonazola zvišali, in sicer AUC za 44%, Cmax pa za 19%.
The AUC and Cmax of amprenavir were increased by 31% and decreased by 16%, respectively.
AUC amprenavirja se je zvišala za 31%, Cmax amprenavirja pa znižala za 16%.
Co- administration of fosamprenavir 700 mg with ritonavir 100 mg twice daily and ketoconazole 200 mg once daily increased plasma ketoconazole Cmax by 25% and increased AUC(0-τ) to values 2.69-fold those observed on administration of ketoconazole 200 mg once daily without concurrent fosamprenavir with ritonavir.
Pri sočasni uporabi fosamprenavirja v odmerku 700 mg skupaj z ritonavirjem v odmerku 100 mg dvakrat na dan in ketokonazola v odmerku 200 mg enkrat na dan se je plazemska Cmax ketokonazola zvišala za 25%, vrednosti AUC( 0- τ) ketokonazola pa so bile za 2, 69- krat višje kot pri uporabi ketokonazola v odmerku 200 mg enkrat na dan brez sočasne uporabe fosamprenavirja z ritonavirjem.
When used with Agenerase with ritonavir, high doses (> 200 mg/ day) of ketoconazole or itraconazole are not recommended.
Pri sočasni uporabi skupaj z zdravilom Agenerase in ritonavirjem uporaba visokih odmerkov (> 200 mg/ dan) ketokonazola ali itrakonazola ni priporočljiva.
Antacids: on the basis of the data for other protease inhibitors, it is advisable not to take antacids at the same time as Agenerase, since its absorption may be impaired.
Na osnovi podatkov za druge zaviralce proteaz je priporočljivo, da se antacidi ne jemljejo sočasno z zdravilom Agenerase, ker bi lahko prišlo do motenj absorpcije slednjega.
Anticonvulsant active substances: concomitant administration of anticonvulsant active substances known as enzymatic inductors (phenytoin, phenobarbital, carbamazepine) with amprenavir may lead to a decrease in the plasma concentrations of amprenavir.
Zaradi sočasne uporabe antiepileptikov, ki so znani induktorji encimov (fenitoin, fenobarbital, karbamazepin) skupaj z amprenavirjem se lahko zmanjšajo koncentracije amprenavirja v plazmi.
These combinations should be used with caution and therapeutic concentration monitoring is recommended (see section 4.4).
Priporočamo nadziranje terapevtskih koncentracij (glejte poglavje 4. 4).
Calcium-channel blockers: amprenavir may lead to increased serum concentrations of calcium channel blockers such as amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine and verapamil, possibly resulting in enhanced activity and toxicity of these medicinal products.
Amprenavir lahko povzroči povišanje serumskih koncentracij zaviralcev kalcijevih kanalčkov, kot so amlodipin, diltiazem, felodipin, isradipin, nikardipin, nifedipin,
Erectile dysfunction agents: based on data for other protease inhibitors caution should be used when prescribing PDE5 inhibitors (e. g. sildenafil and vardenafil) to patients receiving Agenerase.
Na osnovi podatkov za druge zaviralce proteaz je ob predpisovanju zaviralcev PDE5 (npr. sildenafil in vardenafil) bolnikom, ki prejemajo zdravilo Agenerase, potrebna previdnost.